Accueil > Revues > Médecine > European Journal of Dermatology > Texte intégral de l'article
 
      Recherche avancée    Panier    English version 
 
Nouveautés
Catalogue/Recherche
Collections
Toutes les revues
Médecine
European Journal of Dermatology
- Numéro en cours
- Archives
- S'abonner
- Commander un       numéro
- Plus d'infos
Biologie et recherche
Santé publique
Agronomie et Biotech.
Mon compte
Mot de passe oublié ?
Activer mon compte
S'abonner
Licences IP
- Mode d'emploi
- Demande de devis
- Contrat de licence
Commander un numéro
Articles à la carte
Newsletters
Publier chez JLE
Revues
Ouvrages
Espace annonceurs
Droits étrangers
Diffuseurs



 

Texte intégral de l'article
 
  Version imprimable
  Version PDF

Atopic eczema complicated by systemic lupus erythematosus


European Journal of Dermatology. Volume 15, Numéro 6, 500-2, November-December 2005, Clinical report


Summary  

Auteur(s) : Naoyuki Higashi, Seiji Kawana , Department of Dermatology, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 1138603, Japan.

Illustrations

ARTICLE

Auteur(s) : Naoyuki Higashi, Seiji Kawana

Department of Dermatology, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 1138603, Japan

accepté le 3 Mars 2005

A topic diseases entail a hyperreactivity towards environmental antigens [1], whereas autoimmune diseases show hyperreactivity towards endogenous antigens. Therefore the two conditions could be mutually exclusive. So far there have only been a few case reports of patients displaying both atopic eczema (AE) and systemic lupus erythematosus (SLE). Both diseases express an enhanced Th2 cytokine profile [2]. Also, several autoantibodies have been detected in patients with AE [3, 4]. And 20 to 30% of AE patients show positive antinuclear antibodies (ANA) [5], but their significance is unclear. Recent reports have indicated that the incidence of AE in SLE is comparable to persons without SLE [6, 7]. Here, we present two patients with AE who developed SLE.

Case reports

Case 1

A 25-year-old man was admitted complaining of fever (37.5°C) and butterfly erythema ( (figure 1A) ). He had no active symptoms of AE at admission, but had suffered from mild to moderate AE since 5 years of age. His elder sister had also suffered from AE. He had been treated with topical steroids, moisturizing cream and oral anti-histamine in our outpatient clinic 3 years previously. Poikiloderma-like changes in his neck were observed as a clinical appearance of chronic AE. In addition he had Raynaud’s phenomenon. Five years before admission he was found to have increased anti-RNP antibodies (> 500 U/ml), but was not diagnosed as having mixed connective tissue disease (MCTD). Three years before the present admission he was diagnosed with nephritic syndrome (membranous nephropathy, stage II~III). On this admission, blood tests were normal except for increased lactate dehydrogenase (LDH) 648 IU/l (normal range 180-460 IU/l). Urinalysis revealed proteinuria (0.3 g/day). His immunological findings are summarized in table 1. A facial skin biopsy showed hyperkeratotic changes, follicular plugging, thinning of epidermis, slight degeneration of the basal layer, edema in upper dermis and a predominantly lymphocytic infiltration around hair follicles and appendages compatible with LE ( (figure 1B) ). The lupus band test revealed a moderate granular deposition of IgG, C3 in the dermis-epidermis junction. A new renal biopsy showed membranous nephropathy stage III. He was diagnosed as suffering from SLE, and steroid therapy (30 mg/day) [8] was effective in controlling his symptoms. His AE was treated with only moisturizing cream due to the treatment with systemic steroids.

Case 2

A 27-year-old man had suffered from mild AE since childhood. His elder brother had also AE. He was admitted complaining of facial edema and an acne-like eruption ( (figure 2) ) but without eczema. His past history besides AE was allergic rhinitis. Blood tests showed slight leukopenia, slightly elevated GOT, BUN and creatinine, increased total cholesterol and decreased total protein and albumin. Urinalysis revealed proteinuria (4.1 g/day), 50-99 erythrocytes, and 20-29 granular and hyaline casts per high-power field. The main immunological findings are summarized in table 1. A skin biopsy from a chilblain-like lesion showed changes compatible with LE. A renal biopsy showed lupus nephritis IV b. He was started on prednisolone 60 mg/day with much improvement.

Discussion

We present two patients with AE, who developed SLE. Case 1 fulfilled four of the revised American Rheumatism Association (ARA) criteria for SLE [8]. He had manifestations of MCTD, but did not strictly fulfill the criteria for a diagnosis of MCTD [9]. Case 2 satisfied five of the revised ARA criteria for SLE [8]. He was treated for AE in childhood. He had normal IgE, but a positive RAST to pollen. Histologically there was slight liquefaction degeneration of the basal layer of the epidermis and the lupus band test was positive in both cases. It is noteworthy that both were males, as 90% of patients with SLE are females. Interestingly, Case 1 developed SLE during treatment of mild AE in our department. Case 2 did not have any active symptoms of AE, but had a past history of AE.

Recently, Sekigawa et al. reported 2 cases of AE associated with MCTD-like immune abnormalities [10]. Although both cases had a high titer of anti-RNP Ab, they did not fulfill the criteria for a diagnosis of MCTD [9]. Only 4 patients with AE have been reported to develop SLE in conference abstracts in Japan. The 4 reported patients were female, unlike our cases. The reason why there are few case reports of AE with SLE is unknown. It is unlikely that two morbid conditions, AE and SLE, simultaneously exist in an individual. Another conceivable reason may be the difference of developmental age between AE and SLE. When a patient developed SLE, no symptom of AE was generally found, due to self-healing in AE, like our case 2. Thus we considered case 1 a very rare status.

Sekigawa reported that the incidence of AE was 6% in SLE patients, comparable to that in healthy control (15%) [7]. In accordance with this report, among 33 patients with SLE in our department, four had suffered from AE (12.1%). There was only 1 case who developed SLE during treatment of active symptoms of AE. Thus we reconsidered case 1 as a very rare patient, because Morton and Sekigawa referred the past history of AE in SLE.

Several autoantibodies have been detected in patients with AE [3, 4]. Between 20 to 30 % of AE patients have ANA ranging in titer between 1:40 and 1:1280 [5]. Nineteen percent of patients with AE in our department had positive ANA (range 1:40 to 1:640). We do not know whether ANA (+) patients with AE will develop autoimmune disease or not. Case 1 had a high titer of anti-RNP Ab before development of SLE. Thus it is necessary to measure various autoantibodies in ANA (+) patients with AE and to carefully monitor those AE patients for a long period for development of SLE symptoms, if other autoantibodies are positive in ANA (+) patients with AE.

Becker described a relationship between AE and other autoimmune disease such as SLE, Crohn’s disease and rheumatoid arthritis, as there is an overlap of autoimmune/inflammatory loci on 1p22.3-p22.1 (TGFbRIII), on 3q21-q22.2 (CD80, CD86) and on 19p13 suggesting that underlying genetic components may not be disease or tissue specific, but may share basic mechanisms of immune regulation [11].

Further investigations should clarify the relationship between AE and SLE and thus contribute to reveal pathophysiological features of AE and SLE.

Acknowledgments

This work was supported in part by grants-in-aid 14770433 (NH) from the Ministry of Education, Science and Culture of Japan. We thank Dr. Kristian Thestrup-Pedersen for his helpful comments during the preparation of this manuscript.

References

1 Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, et al. A revised nomenclature for allergy. Allergy 2001; 56: 813-24.

2 Romagnani S. Lymphokine production by human T cells in disease states. Rev Immunol (Paris) 1994; 12: 227-57.

3 Ohkouchi K, Mizutani H, Tanaka M, Takahashi M, Nakashima K, Shimizu M. Anti-elongation factor-1α autoantibody in adult atopic dermatitis patients. Int Immunol 1999; 11: 1635-40.

4 Ochs RL, Muro Y, Si Y, Ge H, Chan EKL, Tan EM. Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol 2000; 105: 1211-20.

5 Taniguchi Y, Yamakami T, Sakamoto T, Nakamura Y, Okada H, Tanaka H, et al. Positive antinuclear antibody in atopic dermatitis. Acta Derm Venereol (Stockh) 1992(Suppl. 176): 62-4.

6 Morton S, Palmer B, Muir K, Powell RJ. IgE and non-IgE mediated allergic disorders in systemic lupus erythematosus. Ann Rheum Dis 1998; 57: 660-3.

7 Sekigawa I, Yoshiike T, Iida N, Hashimoto H, Ogawa H. Allergic disorders in systemic lupus erythematosus: prevalence and family history. Lupus 2002; 11: 426-9.

8 Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.

9 Wallace DJ. Differential diagnosis and disease associations. In: Wallance DJ, Harn BH, eds. Dubois lupus erythematosus. 5th ed. Baltimore: Williams & Wilkins, 1997: 943-65.

10 Sekigawa I, Yoshiike T, Iida N, Hashimoto H, Ogawa H. Two cases of atopic dermatitis associated with autoimmune abnormalities. Rheumatology 2003; 42: 184-5.

11 Becker KG, Barnes KC. Underlying disease specificity of genetic loci in atopic dermatitis. J Invest Dermatol 2001; 117: 1325-7.


 

Qui sommes-nous ? - Contactez-nous - Conditions d'utilisation - Paiement sécurisé
Actualités - Les congrès
Copyright © 2007 John Libbey Eurotext - Tous droits réservés
[ Informations légales - Powered by Dolomède ]